Clinical Trials

Do you or your child have a lung disease? This study will investigate the genes involved in the breathing process and in the development of lung diseases such as asthma or sarcoidosis to improve understanding of the role they play. To participate in this study, you or your child must be between 2 and 90 years old. This study is located in Bethesda, Maryland, at the NIH Clinical Center.

Are you an adult who has had asthma for longer than a year? This study will gather general information over a 20-year period about people who have had asthma to understand why patients respond differently to treatment. To participate in this study, you must be age 18 or older, have been diagnosed with asthma for at least one year, and not have any other major conditions. This study is located in Bethesda, Maryland.

Do you have asthma or would you like to help research on asthma? This study will look at the differences between cells from the airways of people who do and do not have asthma. Doctors will use a procedure called bronchoscopy to collect cells. To participate in this study, you must be between 18 and 75 years old, not have HIV, and not be pregnant or planning to become pregnant. This study is located in Bethesda, Maryland.

Are you an adult with both asthma and obesity? This study is testing whether a medicine called L-citrulline can help treat asthma and improve lung function in people who have obesity. To participate in this study, you must be 18 to 65 years old and have asthma and obesity. This study takes place in Durham, North Carolina.

Are you an adult with atrial fibrillation? In this study, researchers are comparing a continuous direct oral anticoagulation (DOAC) use versus time-limited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) for persons with atrial fibrillation and a moderate risk of stroke. Participants must be between the ages of 22 and 85 and have a history of atrial fibrillation. The study is taking place at locations in California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, South Carolina, Texas, Virginia, Wisconsin, and Washington, D.C.

Did you develop atrial fibrillation after coronary artery bypass graft (CABG) surgery? Did you develop atrial fibrillation after a coronary artery bypass grafting (CABG) surgery? This study is looking at how well oral anticoagulation medicines work to prevent complications, such as blood clots and heart attack, for patients who experience post-operative atrial fibrillation (POAF). This study is in multiple locations around the country.

The Bashir™ Endovascular Catheter has been designed to administer therapeutic agents in the peripheral vasculature. Because of the unique design of the catheter, with its six expandable infusion limbs, the Bashir™ Endovascular Catheter has the ability to: 1. Create a much larger central channel for blood flow, thereby utilizing the body's own endogenous fibrinolytic agents to lyse the clot, and 2. Greatly enhance the radial dispersion of a catheter-administered thrombolytic agent throughout the thrombus. Expansion of the multiple arms of the basket in the infusion catheter causes fissuring of the clot. The net result is that a greater surface area of clot is exposed to both endogenous and exogenously administered lytic agents, thereby promoting clot dissolution.